Cheap Broker Fees
Sinovac Biotech Ltd is a biotechnology business based in the US. Sinovac Biotech shares (SVA) are listed on the NASDAQ and all prices are listed in US Dollars. Sinovac Biotech employs 1,959 staff and has a trailing 12-month revenue of around USD$510.6 million.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$6.47|
|52-week range||$6.47 - $6.47|
|50-day moving average||$6.47|
|200-day moving average||$6.47|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.97|
|1 week (2021-10-12)||6.47|
|1 month (2021-09-17)||6.47|
|3 months (2021-07-19)||6.47|
|6 months (2021-04-19)||6.47|
|1 year (2020-10-15)||N/A|
|2 years (2019-10-15)||N/A|
|3 years (2018-10-19)||7.51|
|5 years (2016-10-19)||9.29%|
Valuing Sinovac Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sinovac Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sinovac Biotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Sinovac Biotech shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sinovac Biotech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $219.5 million.
The EBITDA is a measure of a Sinovac Biotech's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$510.6 million|
|Operating margin TTM||42.26%|
|Gross profit TTM||$443.4 million|
|Return on assets TTM||11.46%|
|Return on equity TTM||25.16%|
|Market capitalisation||$642.4 million|
TTM: trailing 12 months
There are currently 188,500 Sinovac Biotech shares held short by investors – that's known as Sinovac Biotech's "short interest". This figure is 0% down from 188,500 last month.
There are a few different ways that this level of interest in shorting Sinovac Biotech shares can be evaluated.
Sinovac Biotech's "short interest ratio" (SIR) is the quantity of Sinovac Biotech shares currently shorted divided by the average quantity of Sinovac Biotech shares traded daily (recently around inf billion). Sinovac Biotech's SIR currently stands at 0. In other words for every 100,000 Sinovac Biotech shares traded daily on the market, roughly 0 shares are currently held short.
However Sinovac Biotech's short interest can also be evaluated against the total number of Sinovac Biotech shares, or, against the total number of tradable Sinovac Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sinovac Biotech's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sinovac Biotech shares in existence, roughly 0 shares are currently held short) or 0.0032% of the tradable shares (for every 100,000 tradable Sinovac Biotech shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sinovac Biotech.
We're not expecting Sinovac Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Sinovac Biotech's shares have ranged in value from as little as $6.47 up to $6.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sinovac Biotech's is 0.0529. This would suggest that Sinovac Biotech's shares are less volatile than average (for this exchange).
Sinovac Biotech Ltd. , a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu. 1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.